Atopic dermatitis treatment: Current state of the art and emerging therapies

Jonathan I. Silverberg*

*Corresponding author for this work

Research output: Contribution to journalArticle

13 Scopus citations

Abstract

Background: Atopic dermatitis (AD) can be debilitating and often requires the use of combination topical and systemic therapy to achieve adequate disease control. Methods: A non-systematic review was performed of current state of the art and emerging therapies for AD. Results: There are a number of topical agents approved by the U.S. Food and Drug Administration (FDA) for the treatment of AD and multiple nonapproved systemic agents that are used off label for the treatment of AD. All of these have limitations of efficacy and/or safety, which leads to a number of unmet disease-treatment needs. Recent insight has identified a number of novel pathways as treatment targets for AD, including the T-helper type 2 cytokines, interleukins (IL) 4, IL-13, IL-33, phosphodiesterase E 4, and Janus kinase signaling. Dupilumab is a monoclonal antibody that inhibits interleukin 4 and 13 signaling and was recently approved by the FDA for the treatment of moderate-severe AD in adults. Discussion: There are a number of current treatment approaches and emerging therapies for AD.

Original languageEnglish (US)
Pages (from-to)243-249
Number of pages7
JournalAllergy and asthma proceedings
Volume38
Issue number4
DOIs
StatePublished - Jul 1 2017

ASJC Scopus subject areas

  • Immunology and Allergy
  • Pulmonary and Respiratory Medicine

Fingerprint Dive into the research topics of 'Atopic dermatitis treatment: Current state of the art and emerging therapies'. Together they form a unique fingerprint.

Cite this